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A B S T R A C T
Chiral pharmaceutically active compounds (cPACs) are not currently governed by environmental regulation yet
are expected to be in the future. As cPACs can exert stereospecific toxicity in the aquatic environment, it is
essential to better understand their stereoselective behaviour here. Therefore, this study aims to provide a new
perspective towards comprehensive evaluation of cPACs at a river catchment level, including their stereo-
chemistry as a chemical phenomenon driving fate of chiral molecules in the environment. A large spatial and
temporal monitoring program was performed in Southwest England. It included 5 sewage treatment works and
the receiving waters of the largest river catchment in Southwest England. Simultaneously, lab-scale microcosm
studies in simulated activated sludge bioreactors and river water microcosm were performed to evaluate ste-
reoselective degradation of cPACs. A multi-residue enantioselective method allowed the analysis of a total of 18
pairs of enantiomers and 3 single enantiomers in wastewater and river water samples.
Our monitoring program revealed: (1) spatial and temporal variations of cPACs in influent wastewaters re-
sulting from different patterns of usage as well as an (2) enantiomeric enrichment of cPACs, likely due to human
metabolism, despite their commercialization as racemic mixtures. A similar chiral signature was observed in
effluent and receiving waters. Stereoselective degradation was observed in trickling filters (TF) for naproxen,
ketoprofen, cetirizine and 10,11-dihydroxy-10-hydroxycarbamazepine, in sequencing batch reactors (SBR) for
ifosfamide and in activated sludge (AS) for cetirizine. The extent of enantiomer-specific fate was wastewater
treatment dependent in the case of naproxen (TF showed higher stereoselectivity than AS and SBR) and cetir-
izine (TF and AS showed higher stereoselectivity than SBR) due to differing microbial population. Furthermore,
stereoselective degradation of naproxen was highly variable among STWs using similar treatments (TF) and
operating in the same region. Microbial stereoselective degradation was also confirmed by both activated and
river water simulated microcosm for chloramphenicol, ketoprofen, indoprofen, naproxen and 10,11-dihydroxy-
10-hydroxycarbamazepine. Results from our large scale river catchment monitoring study and lab simulated
microcosm show wide-ranging implications of enantiomerism of cPACs on environmental risk assessment (ERA).
As two enantiomers of the same compound show different biological effects (e.g. toxicity), their non-racemic
presence in the environment might lead to inaccurate ERA. This is because current ERA approaches do not
require analysis at enantiomeric level.
1. Introduction
Substantial attention has been given to the presence of pharma-
ceutically active compounds (PACs) in environmental matrices because
of their ubiquity and potential ecological risks (Cizmas et al., 2015;
Ebele et al., 2017). However, there is a limited understanding of the
environmental fate and effects of chiral PACs (cPACs) at the en-
antiomeric level mainly due to the absence of adequate enantioselective
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analytical methods (Camacho-Muñoz et al., 2016a; Kasprzyk-Hordern,
2010; Sanganyado et al., 2017; Zhou et al., 2018). Enantiomers of
cPACs often exhibit different pharmacokinetics and pharmacodynamics
that can result in enantiomer dependent toxicity, due to the inherent
stereospecificity of biological processes. For example, the therapeutic
effect of non-steroidal anti-inflammatory drugs resides almost ex-
clusively in the S-enantiomer (S-(+)-ibuprofen is 110 times more active
than R-(−)-ibuprofen (Adams et al., 1976; Villaneuva et al., 1993))
whereas the R-enantiomer are partly active, inactive or toxic (naproxen
is prescribed as S-(+)-naproxen because the R-enantiomer is suspected
to be a liver toxin (Harrington and Lodewijk, 1997)); they can also be
enantiomer-specific towards aquatic organisms (R-(−)-fluoxetine is 30
times more toxic to the protozoan T. thermophila and more harmful to
the algae P. subcapitata than S-(+) fluoxetine whereas S-(+)-fluoxetine
is 10 times more toxic to the fish P. promelas than its antipode (Andrés-
Costa et al., 2017; De Andrés et al., 2009). In spite of this well-estab-
lished enantiomer-specific toxicity, many cPACs are commercialized as
an equal mixture of both enantiomers known as a racemic mixture and
indicated by an enantiomeric fraction (EF) of 0.5.
Little is known about the enantiomeric compositions and fate of
cPACs in the aquatic environment. cPACs are continuously excreted or
disposed into the sewer systems as the unaltered parent compound or as
metabolites in racemic or non-racemic mixtures. Sewage treatment
works (STWs) are designed to reduce loads of nutrients and organic
matter but not to remove cPACs, making them a major point-source of
pollution in many aquatic systems (Archer et al., 2017; Camacho-
Muñoz et al., 2016a; Camacho-Muñoz et al., 2016b; Duan et al., 2018;
Evans et al., 2017; Sanganyado et al., 2017). Moreover, removal effi-
ciencies depend on a high number of variables such as the wastewater
treatment process, operational variables of the STW, physicochemical
properties of the cPAC and/or meteorological conditions.
Growing evidence has demonstrated the stereoselective behaviours
of cPACs in wastewater, sludge and river water systems (Camacho-
Muñoz and Kasprzyk-Hordern, 2015; Camacho-Muñoz et al., 2016b;
Evans et al., 2017; Kasprzyk-Hordern and Baker, 2012). During was-
tewater treatment and in the receiving aquatic environment, cPACs
undergo a series of physical (e.g., dilution, volatilization, and sorption),
chemical (e.g., hydrolysis, photolysis, sorption, and oxidation) and
biological (e.g., biodegradation and biotransformation) attenuation
processes. Whereas abiotic processes such as volatilization or photo-
degradation are non-enantioselective, biotic processes such as meta-
bolism and microbial degradation may alter the EF due to selective
transformations (Baker and Kasprzyk-Hordern, 2013; Kasprzyk-
Hordern, 2010; Kasprzyk-Hordern and Baker, 2012; MacLeod et al.,
2007; MacLeod and Wong, 2010; Nikolai et al., 2006; Ribeiro et al.,
2012). These changes in the EF can provide insights of the compound's
history, as well as pointing to the nature and sources of environmental
pollution (Camacho-Muñoz et al., 2016a; Petrie et al., 2015). For ex-
ample, since biodegradation can be enantioselective, EF has been pro-
posed as an innovative tool for in situ assessment of biodegradation
processes in the environment or to distinguish between direct or in-
direct disposal (Bagnall et al., 2013; Camacho-Muñoz et al., 2016a;
Escuder-Gilabert et al., 2018; Hashim et al., 2011; Maia et al., 2017;
Petrie et al., 2015). Furthermore, the development of appropriate en-
vironmental legislation is governed by having robust data sets on the
occurrence and fate of cPACs in the environment. As toxicity of cPACs
in the environment can be stereospecific, it is essential to better un-
derstand the enantiomeric composition and behaviour of cPACs in the
environment. This will enable more accurate environmental risk as-
sessment to be undertaken as current guidelines do not consider ste-
reochemistry (Directive 2013/39/EU).
This study aims to provide a new perspective towards comprehen-
sive evaluation of cPACs at a river catchment level, including their
stereochemistry as a chemical phenomenon driving the fate of chiral
molecules in the environment. Therefore, we designed and conducted a
field study which involved spatial and temporal sampling campaigns
along a river catchment that covers an area of approximately 2000 km2
in Southwest England. Spatial and temporal composite sampling cam-
paigns in 5 STWs, with different wastewater treatments, that account
for 75% of contributing population (≈1.5 million) in the catchment.
The objectives of this study were: (i) to investigate the fate and beha-
viour of cPACs during wastewater treatment; and (ii) to assess the
impact of effluent discharges to river quality. In addition, evidence
suggests that stereoselectivity is biological in nature; therefore research
in this area is crucial to get a better understanding of environmental
impacts resulting from the stereoselective disposition of cPACs in any
biodegradation pathway that could lead to a significant under or
overestimation of the risks posed by these compounds. Consequently,
we performed controlled lab-scale microcosm studies: (iii) to evaluate
the stereoselective degradation of a wide group of cPACs in river water
and activated sludge simulating microcosm experiments under different
experimental conditions (biotic, abiotic, light and dark conditions); (iv)
to investigate if EF can be used to distinguish between different natural
attenuation processes; and (v) to provide insights into biodegradation
pathways and the capacity of receiving waters to deal with those cPACs.
2. Experimental
2.1. Chemicals and reagents
Selection of cPACs was based on their high usage, occurrence and
ubiquity in the environment and possibility of chiral inversion during
biotic processes. HPLC-grade acetonitrile (≥99.9%), methanol (≥99.9%),
ammonium acetate (≥99.0%), formic acid (≥96.0%) and sodium azide
were supplied by Sigma-Aldrich. Ultrapure water was obtained from a
water purification system (MilliQ system, UK). R/S(± )-aminorex, caf-
feine, R/S(± )-carboxyibuprofen (mixture of diastereomers), 6R,7R,2R-
cephalexin, S-(+)-O-desmethylnaproxen, 1R,2S-(−)-florfenicol, R/S
(± )-2-hydroxyibuprofen, R/S(± )-ibuprofen, R/S(± )-ifosfamide, R/S
(± )-indoprofen, R/S(± )-ketoprofen, S-(+)-ketoprofen, R/S(± )-man-
delic acid, R/S(± )-2-phenylpropionic acid, R/S(± )-praziquantel, R/S
(± )-tetramisole hydrochloride, S-(−)-tetramisole hydrochloride (known
as levamisole) and 1R,2R-(−)-chloramphenicol were purchased from
Sigma-Aldrich (Gillingham, UK). 6R,7R,2S-cephalexin, R/S(± )-3-N-de-
chloroethylifosfamide, R/S(± )-dihydroketoprofen (mixture of diaster-
eomers), R/S(± )-naproxen and S-(+)-naproxen were obtained from
Toronto Research Chemicals Inc. (Ontario, Canada). R/S(± )-10,11-di-
hydro-10-hydroxycarbamazepine, R/S(± )-fexofenadine hydrochloride,
R/S(± )-cetirizine dihydrochloride and 1S,2S-(+)-chloramphenicol were
supplied by LGC Standards (Teddington, UK). 1R,2R-(−)-chloramphenicol
base and S-(+)-ibuprofen were purchased from Fisher. Chemical struc-
tures, and physicochemical properties of the studied compounds can be
found in Camacho-Muñoz and Kasprzyk-Hordern (2015).
Surrogate/internal standards (IS): (± )-chloramphenicol-d5, R/S
(± )-ibuprofen-d3, R/S(± )-ifosfamide-d4, R/S(± )-ketoprofen-d3, R/
S(± )-naproxen-d3, R/S(± )-praziquantel-(cyclohexyl-d11) and R/S
(± )-tetramisole-d5 hydrochloride were purchased from LGC Standards
(Teddington, UK) and Sigma-Aldrich (Gillingham, UK).
All standards were of high purity grade. Stock solutions of each
compound (1mgmL−1) were prepared in methanol and stored at
−18 °C. Working solutions were prepared by diluting stock solution in
methanol and stored at −18 °C. All glassware was deactivated with
dimethylchlorosilane (5% DMDCS in toluene, Sigma-Aldrich). Oasis
HLB (3 cm3, 60mg) and MAX (3 cm3, 60mg) cartridges were purchased
from Waters (Milford, MA, USA).
2.2. The catchment sampling campaign
The study area is located in the Southwest of the UK. The river
catchment covers an area of approximately 2000 km2 (Fig. S1). The
population within the catchment is ~1.5 million. The sampling cam-
paign was conducted in 2015 from June to October. Care was taken to
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avoid days in which heavy rainfall occurred to avoid losses due to
overflow. At each site, sampling was conducted for 7 consecutive days
running from Wednesday to Tuesday. Wastewater was collected as
volume proportional 24 h composites (80mL every 15min, 4 °C) and
pooled after 24 h from five major STWs (named STWs A–E) receiving
wastewater from 75% of population. STW A uses conventional acti-
vated sludge (AS), STW B–D uses tricking filter beds (TF) and STW E
uses sequencing batch reactors (SBR). Influent wastewater was col-
lected between screening and primary sedimentation. Grab activated
sludge samples were collected from STW E. River waters (8 L) were
collected as grab samples upstream and downstream of each effluent
discharge point at varying distances depending on accessibility.
Downstream samples were collected at a minimum of 0.5 km below the
effluent discharge point (Table S1), except in the case of STW A which
was taken close to the effluent discharge point due to no suitable access
point. STW A is the site studied furthest up the river catchment and is in
a rural location. River water was not collected for site E as the STW
discharges directly to the estuary. All samples were then returned to the
laboratory on ice to maintain a temperature of approximately 4 °C and
processed immediately upon arrival to the laboratory. ISs were added
before samples were filtered through 0.7-μm glass fiber filters
(Whatman, UK).
2.3. Microcosm bioreactors
2.3.1. Sample collection
Samples were collected as discussed in Section 2.2 in February
2015. Microcosm bioreactors were set up within 2 h after sample col-
lection.
2.3.2. Study of mixed compounds bioreactors in activated sludge
microcosm: Influence of biotic processes
Activated sludge microcosms were conducted in the dark with or
without sodium azide (as an inhibitor to biotic processes) in duplicate
(Fig. S2B). Six conical flasks (made of borosilicate 3.3 glass) were au-
toclaved prior to use. Four empty flasks were spiked with a mixture of
the compounds (R/S(± )-naproxen, R/S(± )-ketoprofen, R/S(± )-in-
doprofen, R/S(± )-tetramisole, R/S(± )-praziquantel, R/S(± )-ifosfa-
mide, R/S(± )-10,11-dihydro-10hydroxycarbamazepine and R/S
(± )-chloramphenicol) prepared in methanol and the methanol al-
lowed to evaporate before adding the sample. Subsequently, 2 L of
unfiltered activated sludge were added to each flask and they were
placed onto a magnetic stirrer. Three bioreactors were spiked with so-
dium azide (1 g L−1). Over a 24 h-sampling period, samples (100mL)
were collected at 0 h (before and after spiking), 0.5 h, 1 h, 1.5 h, 2 h,
3 h, 5 h, 8 h, 12 h and 24 h. After collection samples were spiked with a
mixed solution of deuterated ISs (1 μg L−1). Dissolved oxygen, pH and
temperature were measured each sampling time to verify bioreactor
performance (Fig. S3).
2.3.3. Study of mixed compounds bioreactors in river water microcosm:
influence of biotic (microbial degradation) and abiotic processes
(photochemical processes)
River water microcosms were conducted as previously described by
Bagnall et al. (2013). In summary, degradation experiments were
conducted in the light and dark (to study photochemical processes),
with or without sodium azide (as an inhibitor to biotic processes) in
duplicate (Fig. S2A). Eight conical flasks (made of borosilicate 3.3 glass
with no visible light absorption and UV light cut-off at< 275 nm) were
autoclaved prior to use. Each empty flask was spiked with a mixture of
the compounds (R/S(± )-naproxen, R/S(± )-ketoprofen, R/S(± )-in-
doprofen, R/S(± )-tetramisole, R/S(± )-praziquantel, R/S(± )-ifosfa-
mide, R/S(± )-10,11-dihydro-10hydroxycarbamazepine and R/S
(± )-chloramphenicol) prepared in methanol and the methanol al-
lowed to evaporate before adding the sample. Subsequently, 2 L of
unfiltered river water were added to each flask and they were placed
onto a magnetic stirrer. Four bioreactors were spiked with sodium azide
(1 g L−1) to inhibit biotic processes while the four remaining were not
spiked to allow biotic processes take place. Four bioreactors were in-
cubated in the dark (two replicate microcosms with and two without
sodium azide) and four bioreactors were incubated in the light (two
replicate microcosms with and two without sodium azide). Daylight
conditions were simulated using an Osram 400W HQI BT daylight lamp
for 8 h each day of the experiment. Over a month sampling period,
samples (200mL) were collected on day 1 (before and after spiking), 2,
3, 5, 7, 9, 12, 15, 22 and 30. After collection, samples were spiked with
a mixed solution of deuterated ISs (1 μg L−1). Dissolved oxygen, pH,
temperature and photon flux measurements were measured each sam-
pling day during the sampling period to verify bioreactor performance
(Fig. S3). Average photon flux measured at the level of the bottle base
was 388 μmol/m2/s.
2.4. SPE and analysis
The analytical methodology used and validation parameters are
discussed previously in Camacho-Muñoz and Kasprzyk-Hordern (2015).
Briefly, Oasis HLB-MAX cartridges were set up in tandem and condi-
tioned with methanol and deionized water at pH 7.5. Samples were
spiked with a mixture of ISs, filtered and loaded onto the cartridges.
SPE cartridges were washed individually and then connected in series
afterwards. Analytes were eluted with 4× 1mL methanol and
2×1mL methanol (2% formic acid), eluates evaporated to dryness and
reconstituted with 0.5mL of mobile phase.
The samples were then analysed by chiral LC-MS/MS using an
ACQUITY UPLC™ system (Waters, UK) and a triple quadrupole mass
spectrometer (TQD, Waters, UK) equipped with an electrospray ioni-
sation source. Separation was carried out with a Chiral-AGP
(100× 2mm, i.d. 5 μm) column (Chromtech, UK) and isocratic elution
with mobile phase of 10mM ammonium acetate with 1% acetonitrile
(pH 6.7) at a flow rate of 0.08mLmin−1. Analysis was performed in
positive and negative mode simultaneously. Further details about
chromatographic conditions, MS settings and data analysis are reported
elsewhere (Camacho-Muñoz and Kasprzyk-Hordern, 2015). A quality
assurance and quality control were followed during environmental
sample analysis. It included a series of procedural blanks to monitor for
background contamination, spiked samples and standards prepared in
mobile phase to assess the variability of the analysis. They were in-
jected in triplicate and randomly dispersed throughout sample batches.
2.5. Calculations
Removal efficiency from the aqueous phase during wastewater
treatment was calculated by comparison of the concentration in μg L−1
of each cPAC found in influent (Cinfluent) and in effluent (Ceffluent)
wastewater. In this context, removal efficiencies reported are a com-
bination of degradation and/or formation of transformation products.
Negative removal rates can occur due to desorption of the cPAC from
the solid phase and/or conversion of conjugated metabolites back to the
parent compound (Burns et al., 2018; Verlicchi et al., 2012).
= ×RE C C
C
% 100influent effluent
influent
The mass load of the PACs in the aqueous phase (mg day−1) was
determined using the following equation:
=Mass load mg day C F( )
1000
aqueous1
where Caqueous refers to the concentration of each cPAC expressed as
mg L−1 and F refers to the flow rate expressed as m3 day−1.
The enantiomeric fraction (EF) was calculated with relative (nor-
malised with IS) peak areas as follows:
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where E1 and E2 are concentrations of the first and the second eluting
enantiomer, respectively and (+) and (−) enantiomers if the elution
order is known. EF equals 1 or 0 in the case of single enantiomer form
and 0.5 in the case of racemate.
3. Results and discussion
3.1. Fate of cPACs in the river catchment
3.1.1. cPACs in full scale wastewater treatment plants
3.1.1.1. Occurrence of cPACs in wastewater. A total of 18 pairs of
enantiomers and 3 single enantiomers were analysed in wastewater
and river water samples. Out of the 21 target compounds, 14 were
detected in wastewater samples (R/S(± )-tetramisole, 6R,7R,2R-
cephalexin, 6R,7R,2S-cephalexin, R/S(± )-ifosfamide, R/S(± )-10,11-
dihydro-10-hydroxycarbamazepine, R/S(± )-naproxen, R/S
(± )-ketoprofen, R/S(± )-ibuprofen, R/S(± )-2-phenylpropionic
acid, R/S(± )-mandelic acid, R/S(± )-carboxyibuprofen, R/S
(± )-hydroxyibuprofen, R/S(± )-fexofenadine, R/S(± )-cetirizine
and S-(+)-O-desmethylnaproxen) (Fig. 1). In influent wastewater, the
most dominant cPACs (frequency of detection and mean concentration
in brackets) were S(+)-naproxen (100%, 24.5 μg L−1), R/S(± )-2-
hydroxyibuprofen (100%, 17.8 μg L−1), R/S(± )-fexofenadine (83%,
2.19 μg L−1), R/S(± )-cetirizine (83%, 2.21 μg L−1) and R/S
(± )-tetramisole (74%, 0.09 μg L−1) and in effluents were R/S
(± )-fexofenadine (100%, 2.02 μg L−1), R/S(± )-cetirizine (100%,
5.32 μg L−1), R/S(± )-tetramisole (100%, 0.13 μg L−1) and S-
(+)-naproxen (94%, 2.61 μg L−1).
The highest mass load of cPACs in influent wastewater were found
in STW E (5.64mg day−1) followed by STW C (1.81mg day−1), STW B
(0.52mg day−1), STW A (0.47mg day−1) and STW D (0.23mg day−1).
While the highest mass load in effluent were observed in samples taken
at STW E (0.62mg day−1), followed by STW C (0.59mg day−1), STW B
(0.10mg day−1), STW D (0.88mg day−1) and STW A (0.53mg day−1).
S-(+)-Naproxen and R/S(± )-2-hydroxyibuprofen were found to be the
compounds at the highest concentrations in influent wastewater at all
STWs, up to 54.3 μg L−1 and 29.7 μg L−1, respectively, whereas in ef-
fluent the profile was different (Fig. S4).
3.1.1.2. Enantioselective transformation of cPACs in wastewater. The
enantiomer composition of the commercialized cPACs and their
propensity to stereoselectivity during metabolism are the main factors
which influence the EF values of cPACs observed in influent
wastewater. In effluent samples the microbial activity during
wastewater treatment can lead to further changes in the EF values
observed. Despite being marketed mostly as racemic mixtures, most of
the studied cPACs were found enriched with one enantiomer form in
influent wastewater (Fig. 2). As a note, with the present analytical
method the pair of enantiomers of cephalexin, phenylpropionic acid,
mandelic acid, carboxyibuprofen and hydroxyibuprofen were not
enantioseparated so EF values could not be provided.
3.1.1.2.1. NSAIDs. R/S(± )-Ibuprofen (Fig. 3) was found in effluent
wastewaters from STW B, C and D at mean concentrations of 0.24, 1.00
and 1.21 μg L−1, respectively. Effluent wastewater showed an excess of S-
(+)-ibuprofen (mean EF of 0.71 ± 0.18), likely due to stereoselective
human metabolism and/or microbial metabolic transformation during
wastewater treatment. Although in this study R/S(± )-ibuprofen was not
found in influent wastewater due to analysis issues (Rs was lost due to
high concentration of R/S(± )-ibuprofen in influent wastewater),
published reports confirm that the S-enantiomer is more prevalent in
both influent and effluent wastewater (Buser et al., 1999; Matamoros
et al., 2009; Wang et al., 2013). Despite S-(+)-ibuprofen being around
110 times more potent than the R-enantiomer, ibuprofen is marketed as a
racemic mixture. During metabolism, R-(−)-ibuprofen undergoes chiral
inversion increasing the proportion of S-(+)-ibuprofen in urine, an effect
that has been observed in influent wastewater (Caballo et al., 2015;
Hashim et al., 2011; Matamoros et al., 2009). Removal efficiencies of R/S
(± )-ibuprofen have been reported above 90% regardless of the
wastewater treatment used (Archer et al., 2017; Camacho-Muñoz et al.,
2012; Camacho-Muñoz et al., 2011). Both metabolites of ibuprofen, R/S
(± )-2-hydroxyibuprofen and R/S(± )-carboxyibuprofen were detected
in influents (mean concentration: 17.8 and 2.10 μg L−1, respectively) and
effluents (mean concentration: 0.79 and 0.48 μg L−1, respectively)
(Fig. 1). R/S(± )-2-hydroxyibuprofen was found in the influents of all
the STWs but only in the effluents of STW C (Fig. S4). Mean removal
efficiency of this cPAC was 94.1%. On the other hand R/S
(± )-carboxyibuprofen was only detected in the influents of STW A
and C and in the effluents of STW C and D (Fig. S4) and the removal
efficiencies varied from −40 to 100% between STWs (Fig. 4). The
analytical methodology used in this study did not allow to separate the
pair of enantiomers but in previous studies an enrichment of
the first eluted enantiomer of R/S(± )-2-hydroxyibuprofen and R/S
(± )-carboxyibuprofen were reported (Camacho-Muñoz and Kasprzyk-
Hordern, 2017). This demonstrates the preferential metabolism of R-
(−)-ibuprofen. R/S(± )-2-phenylpropionic acid was detected exclusively
in influent samples of STW C and E at mean concentrations of 0.68 and
1.41 μg L−1, respectively, showing removal efficiencies of 100% in both
STWs.
Naproxen is commercialized as the S-enantiomer due to the known
hepatotoxicity of the R-enantiomer. High concentrations of S-(+)-na-
proxen were found in all influent wastewater samples (mean con-
centration: 32.8, 26.7, 17.6, 28.5, 17.0 μg L−1 in STW A, B, C, D and E,
respectively) (Fig. 3). R-(−)-naproxen was also found in the influents of
STW D at a mean concentration of 0.93 μg L−1. Regardless wastewater
treatment, mean removal efficiency of S-(+)-naproxen resulted to be
higher than 87% and chiral inversion took place in two STWs. R-
(−)-naproxen was found after wastewater treatment in effluents from
STW C and D at mean concentrations of 0.77 and 0.40 μg L−1, respec-
tively (Fig. 4). Mean removal efficiency observed for the R-enantiomer
in STW D was 23%, lower than the one observed for the S-enantiomer
(88%) due to the chiral inversion of the S-enantiomer or to different
deconjugation rates of the conjugate. After wastewater treatment the
mean EF values decreased from 1 to 0.89 ± 0.02 in STW C and from
0.97 ± 0.02 to 0.89 ± 0.03 in STW D (Fig. 3). These changes in the EF
indicate that stereoselective processes took place during wastewater
treatment. EF values reported were consistent with values previously
published elsewhere (Caballo et al., 2015; Hashim et al., 2013; Khan
et al., 2014). The metabolite S-(+)-O-desmethylnaproxen was detected
exclusively in influent wastewater of STW A at mean concentrations of
3.63 μg L−1 and in effluents of STW B (1.24 μg L−1) and C (1.04 μg L−1)
(Fig. S4). The presence of the single S-enantiomer of O-desmethylna-
proxen in effluents and surface water has been reported elsewhere
(Selke et al., 2010). These values were similar to those reported in ef-
fluent wastewater from Sweden (2.51 μg L−1), Pakistan (1.36 μg L−1),
Germany (0.23 μg L−1) and UK (0.22 μg L−1) (Camacho-Muñoz and
Kasprzyk-Hordern, 2015; Larsson et al., 2014; Selke et al., 2010).
Ketoprofen is sold as a racemic mixture despite only S(+)-ketoprofen
exerting the therapeutic effects (Barbanoj et al., 2001). Both enantiomers
of R/S(± )-ketoprofen (Fig. 3) were detected in influent wastewaters from
STW A (0.03 μg L−1) and B (0.22 μg L−1) and in the treated wastewaters of
STW B (0.02 μg L−1) and E (0.31 μg L−1) (Fig. S4). The values of EF in
influents were quite close to the racemic mixture, 0.56 ± 0.06 whereas
higher EF of 0.64 ± 0.05 was observed in effluents (Fig. 2). EF values
were similar to those reported by Hashim et al. (2011) in tertiary treated
wastewater. Degradation of R/S(± ) during wastewater treatments ac-
counted for>59% of S-(+)-ketoprofen and>62% of R-(−)-ketoprofen
and was found to be stereoselective leading to the enrichment of keto-
profen with the S-(+)-enantiomer in effluent wastewaters. The metabolite
R/S(± )-dihydroketoprofen was not detected in any sample.
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Fig. 1. Concentration (μg L−1) of cPACs in influent and effluent wastewater and upstream and downstream river water. Lines in each box show the lower (5%),
median (50%) and upper (95%) percentile. Lines from each box show maximum and minimum concentration values. The point inside each box shows the average
concentration. *Data not available for R/S(± )-ibuprofen in influent wastewater.
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3.1.1.2.2. Anthelmintic drugs. Both enantiomers of tetramisole were
found at similar mean concentrations in influent (0.05 and 0.04 μg L−1
of S-(−)-tetramisole and R-(+)-tetramisole, respectively) and effluent
(0.07 and 0.05 μg L−1 of S-(−)-tetramisole and R-(+)-tetramisole)
wastewater.
Wastewater treatment processes were found not to be effective in
the removal of tetramisole enantiomers from wastewater (mean re-
moval efficiency:< 12% S-(−)-tetramisole and < 6% R-(+)-tetra-
misole) and the mean EF value remained unchanged (EF: 0.47 ± 0.06
and 0.45 ± 0.11 in influent and effluent, respectively) (Fig. 2). How-
ever, differences were found between wastewater treatment plants
(Fig. 4). SBR led to no reduction of R/S(± )-tetramisole, which resulted
in both enantiomers detected in the SBR effluents with an enrichment of
the S-enantiomer (EF: 0.31 ± 0.07). TF and AS revealed a similar re-
moval efficiency of both enantiomers with no stereoselective preference
among them (TF removal: 17% and 8%; AS removal: 8% and 4% of S
and R-tetramisole, respectively) (Fig. 4). Concentrations of S-(−)-le-
vamisole in wastewater up to 0.23 (influent) and 0.18 μg L−1 (effluent)
and mean removal efficiencies of 30% were reported by Čizmić et al.
(2017a).
The anthelmintic activity is associated with the S-enantiomer of
tetramisole. As a result, tetramisole is marketed as enantiomerically
pure S-enantiomer (Thienpont et al., 1969). However, the racemic and
the S-tetramisole have also been used to adulterate illicit drugs
(Bertucci et al., 2014; Casale et al., 2012) which could explain the
presence of the R-enantiomer in wastewater samples. Chiral inversion
or enantiomers deconjugated at different rates could be another ex-
planations for its presence but the information regarding this drug is
scarce. Its metabolite, R/S(± )-aminorex was not detected in any
sample. Further work is therefore required to understand metabolism
and transformation of this compound in the environment.
3.1.1.2.3. Anticancer drugs. The pair of enantiomers of ifosfamide
(Fig. 3) was detected solely in STW E (≈900,000 inhabitants; serving
an urban area with many hospitals) at mean concentrations of
0.006 μg L−1 (E1 and E2) in influent wastewater and at 0.003 μg L−1
of E1 and 0.008 μg L−1 of E2 in effluent wastewater. Removal
efficiencies of ifosfamide enantiomers varied from 0 to 76% (Fig. 4).
Ifosfamide has been reported quite resistant to biodegradation and UV
light, making the use of advanced oxidation processes necessary for its
complete elimination (Franquet-Griell et al., 2017). In this study,
stereoselective degradation of ifosfamide was observed for the first
time during wastewater treatment. A racemic mixture was found in
influent (EF: 0.50 ± 0.03) but the effluent was enriched in the second
eluted enantiomer (EF: 0.21 ± 0.12) (Fig. 3). Concentrations and
removal efficiencies of racemic mixtures are in agreement with those
previously reported by other authors for ifosfamide (Buerge et al.,
2006; Martin et al., 2014; Negreira et al., 2014). The ifosfamide
metabolite was not detected in any analysed sample.
3.1.1.2.4. Antihistamine drugs. Mean concentration of R/S
(± )-cetirizine was lower in influent wastewater (2.21 μg L−1)
compared to treated wastewater (5.32 μg L−1). Moreover, the EF
changed from 0.60 ± 0.11 to 0.39 ± 0.17 after wastewater
treatment, indicating an enrichment of cetirizine with E1-enantiomer
in wastewater influent with subsequent interconversion leading to an
enrichment of cetirizine with E2-enantiomer in wastewater effluent
(likely due to microbial metabolic processes, Fig. 2). In previous
studies, the R-enantiomer has been reported to be stable for
racemization in the living body (Benedetti et al., 2009) and this over-
the counter drug is commercialized both as a single enantiomer (S-
form) and as a racemic mixture what could explain the excess of one of
the enantiomers in the influent and not by stereoselective
transformation in the body. Although cetirizine showed poor removal,
E1 was removed to a greater extent compared to E2, especially after AS
(removal efficiency: 44% E1 and −241% E2) and TF (removal
efficiency: −57% E1 and − 178% E2) treatment (Fig. 4). It is likely
that stereoselective degradation took place. This phenomenon was not
observed after SBR (removal efficiency: 12% E1 and 8% E2) (Fig. 4).
This observation indicates that stereoselective transformation of
cetirizine is wastewater treatment process dependent. Cetirizine
enantiomers have not been investigated before in environmental
samples, and most of the research has been focused on biological
samples. To our knowledge this is the first study reporting a chiral
switch and stereoselective degradation of cetirizine. The R-enantiomer
is the active enantiomer with approximately 30-fold higher affinity for
human histamine H1-receptors than the S-enantiomer. In addition it
shows higher bioavailability than the racemic mixture and due to its
slower metabolism it has a long half-life in the body (Tillement et al.,
2003).
Fig. 2. Concentration (represented by bars) and enantiomeric fraction (represented by symbols) of R/S(± )-ibuprofen, R/S(± )-naproxen, R/S(± )-ketoprofen, R/S
(± )-ifosfamide, R/S(± )-tetramisole, R/S(± )-fexofenadine, R/S(± )-cetirizine and R/S(± )-10,11-dihydro,10-hydroxycarbamazepine in influent and effluent
wastewater. *Data not available for R/S(± )-ibuprofen in influent wastewater.
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Fexofenadine is administered as a racemic mixture because both
enantiomers are biologically active. In this study, mean concentration of
R/S(± )-fexofenadine remained unchanged after wastewater treatment,
2.19 μg L−1 and 2.02 μg L−1 in influent and effluent, respectively
(Fig. 2). Mean removal efficiencies were low:<36% after AS,<6%
after TF and<−48% after SBR. No differences on removal efficiencies
were observed between enantiomers (Fig. 4). Unlike cetirizine, EF values
were similar in both influent and effluent wastewater, 0.50 ± 0.09 and
0.48 ± 0.04, respectively. No stereoselective degradation was observed
for fexofenadine. Similar or lower concentrations of racemic mixtures
were reported elsewhere (Burns et al., 2018; Loos et al., 2013).
3.1.1.2.5. Carbamazepine metabolite. 10,11-Dihydro-10-hydroxycar-
bamazepine E1 was present at lower concentration than its antipode E2
both in influent (0.01 and 0.08 μg L−1 of E1 and E2, respectively) and
effluent (0.001 and 0.006 μg L−1 of E1 and E2, respectively) samples
(Fig. 2) resulting in an EF of 0.07 ± 0.06 and 0.18 ± 0.03, respectively.
10,11-Dihydro-10-hydroxycarbamazepine enantiomers were pre-
sent only in STW B, C and D (Fig. 3). Whereas both enantiomers were
below limit of detection (LOD) in effluents from STW C and D, they
behaved differently in STW B. Removal efficiency of 10,11-dihydro-10-
hydroxycarbamazepine E2 in STW B ranged from 49 to 83%, whereas
E1 was only found in effluent samples but not influent samples ac-
counting for a null removal (Fig. 4). Enantioselective behaviour was
observed in STW B, whereas in influent samples the mean EF value was
0 because only the E2 enantiomer was detected. The mean EF value in
effluent samples was 0.18 ± 0.03. This change in the EF value could be
Fig. 3. Concentration (represented by bars) and enantiomeric fraction (represented by symbols) of R/S(± )-tetramisole, R/S(± )-10,11-dihydro-10-hydro-
xycarbamazepine, R/S(± )-fexofenadine, R/S(± )-cetirizine, R/S(± )-naproxen, R/S(± )-ketoprofen, R/S(± )-ibuprofen and R/S(± )-ifosfamide in influent and
effluent wastewater of STW A-E. *Data not available for R/S(± )-ibuprofen in influent wastewater.
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due to chiral inversion or more likely to the transformation of the
parent compound into its metabolites. Further work is needed to fully
understand stereochemistry of carbamazepine's transformation.
Concentrations of R/S(± )-10,11-dihydro-10-hydroxycarbamazepine
were lower than those reported (at non-stereospecific level) in Germany
(0.5 μg L−1), Portugal (0.3 μg L−1) (Bahlmann et al., 2014) but were si-
milar to those reported in Canada (0.03 μg L−1) (Miao et al., 2005).
3.1.1.2.6. Antibiotic. Mean concentration of cephalexin remained
nearly constant during wastewater treatment (< LOD to 2.88 μg L−1 in
influent wastewater and<LOD to 2.17 μg L−1 in effluent wastewater)
(Fig. S4). Removal efficiency of cephalexin varied depending on the
wastewater treatment used. AS treatment reduced the concentration of
racemic cephalexin by up to 95%, whereas TF treatment achieved
removal efficiencies from −400 to 95% (Fig. 4). It has been previously
reported that TF treatment is superior to AS and anaerobic reactors in
removing microbial loads (Lamba and Ahammad, 2017) which could
lead to a lesser degradation of cephalexin due to less specialized
bacterial communities. The presence of antibiotics in wastewater has
turned STW into hot spots for antibiotic-resistant bacteria and
antibiotic resistant genes because they can alter the bacterial
community structure present in the biological reactors (Novo et al.,
2013; Yang et al., 2014). Due to its similar structure to penicillin and
other β-lactams, cephalexin can be enzymatically hydrolysed by the β-
lactamase enzyme similar to acid hydrolysis. Previous studies have
Fig. 4. Removal efficiencies of cPACs during activated sludge (AS), trickling filter beds (TF) and sequencing batch reactors (SBR). Symbols show the mean removal
efficiency and lines show maximum and minimum removal efficiencies. *Data not available for R/S(± )-ibuprofen.
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shown that conventional wastewater treatment processes are fairly
effective at removing antibiotics but not antibiotic-resistant bacteria
and antibiotic resistant genes (Mao et al., 2015; Narciso-da-Rocha et al.,
2018).
Concentrations reported in this study are higher than those reported
in Iran (up to 0.46 μg L−1 in influents and 0.03 μg L−1 in effluents),
Australia (up to 0.08 μg L−1 in effluents) and China (up to 1.8 μg L−1 in
effluents) (Costanzo et al., 2005; Gulkowska et al., 2008; Mirzaei et al.,
2018).
3.1.1.3. Impact of wastewater treatment technology on cPACs
removal. Considering, the results presented in Section 3.1.1.2,
significant differences were observed in the EF of some cPACs
depending on the wastewater treatment technology used (Figs. 3 and
S6).
Significant changes on the EF value of R/S(± )-naproxen
(p < 0.01), R/S(± )-ketoprofen (p < 0.05), R/S(± )-cetirizine
(p < 0.0001) and R/S(± )-10,11-Dihydro-10-hydroxycarbamazepine
(p < 0.01) were observed after TF wastewater treatment (Fig. S6).
Moreover, stereoselective degradation of naproxen was highly variable
among STWs using TF and operating in the same region (Fig. 4). TF is
an aerobic wastewater treatment that also allows anaerobic organisms
to develop due to its configuration. The significant changes on the EF
values is most likely associated with the presence of a wide microbial
community that comprises aerobic, anaerobic and facultative bacteria,
fungi, algae, and protozoa. In comparison with TF, biological treatment
of AS resulted to be significantly stereoselective only in the case of R/S
(± )-cetirizine (p < 0.0001); and SBR only for R/S(± )-ifosfamide
(p < 0.05). Both AS and SBR are aerobic biological treatments and
although they both have a dense aerobic microbial population it is not
as diverse as the one present in TF. The extent of enantiomer-specific
fate was also wastewater treatment dependent in the case of naproxen
(TF showed higher stereoselectivity than AS and SBR) and cetirizine (TF
and AS showed higher stereoselectivity than SBR) due to differing mi-
crobial populations. Stereoselective fate of cPACs depending on was-
tewater treatment (AS showed higher stereoselectivity than TF in the
case of atenolol) was previously reported (Kasprzyk-Hordern and Baker,
2012). This necessitates further research to fully understand phe-
nomena driving stereoselective fate of cPACs during wastewater treat-
ment.
3.1.2. Occurrence of cPACs in the upstream (control) and downstream
(impact) sites
The frequency of detection, concentration levels and EF of cPACs were
determined to provide information about their distribution and behaviour
and to assess the impact of effluent discharge to river water quality. R/S
(± )-Tetramisole, R/S(± )-10,11-dihydro-10-hydroxycarbamazepine, R/
S(± )-naproxen, R/S(± )-fexofenadine, R/S(± )-cetirizine and R/S
(± )-2-hydroxyibuprofen were detected in upstream (control) and
downstream (impact) river water.
The control sites that showed the highest cPACs mass loads were the
ones further downstream, the ones that have received the highest
number of effluent discharges: site D (1.19mg day−1) > site B
(0.26mgday−1) > site C (0.20mg day−1) > site A (0.07mgday−1). In
the control sites there were no significant daily differences on the total
concentration of cPACs, which ranged from 5.47 μg L−1 to 8.27 μg L−1
(Fig. S5). Overall S-(+)-naproxen (0.35 μg L−1), R/S(± )-2-hydro-
xyibuprofen (0.28 μg L−1), R/S(± )-fexofenadine (0.22 μg L−1 E1 and
0.21 μg L−1 E2), and cetirizine (0.20 μg L−1 E1 and 0.23 μg L−1 E2), were
found at the highest mean concentration levels in control sites (Fig. 1).
In descending order, the highest mass loads discharges were found in
effluents from STW C (0.59mgday−1) > STW B (0.10mgday−1) > STW
D (0.09mgday−1) > STW A (0.05mgday−1). Taking into account the
river flow effluent wastewater should be diluted by a factor of 14 in Site A,
15 in Sites B and C and 113 in Site D. It must be noted that there was no
suitable access points to the river downstream of STW A, so sample was
taken close to the effluent discharge point. No river water was collected for
Site E because the STW discharges directly to the estuary. The impact of
effluent discharges was clearly observed in the mass loads of cPACs found in
the impact sites: site C (1.18mgday−1) > site D (0.90mgday−1) > site B
(0.27mgday−1) > site A (0.17mgday−1). Total amount of cPACs in im-
pact sites increased about 67, 63, 50 and 90% in Site, A, B, C and D, re-
spectively, compared to the ones reported in effluent wastewaters.
In terms of mean concentration levels (Fig. 1), concentrations found
in downstream river water were higher than the ones reported in up-
stream river water (except in the case of fexofenadine), but lower than
the ones reported in effluent wastewater, except in the case of R/S
(± )-10,11-dihydro-10-hydroxycarbamazepine which was similar. No
significant daily differences on the total concentration of cPACs were
observed in the impact sites (7.48–9.35 μg L−1) (Fig. S5). Similar to
control sites, the highest mean concentration levels in impact sites were
found for R/S(± )-cetirizine (0.47 μg L−1 E1 and 0.54 μg L−1 E2), R/S
(± )-hydroxyibuprofen (0.44 μg L−1), S-(+)-naproxen (0.35 μg L−1)
and R/S(± )-fexofenadine (0.14 μg L−1 E1 and 0.15 μg L−1 E2 (Fig. 1).
The EF profile observed in downstream river revealed that it was
enriched in one of the enantiomers (Fig. 5), corresponding, in most
cases, with the chiral profile observed in effluent wastewater.
3.2. Microcosm bioreactors
In order to evaluate processes involved in stereoselective degrada-
tion of a wide group of cPACs, river water and activated sludge simu-
lating microcosm experiments were undertaken under different ex-
perimental conditions (biotic, abiotic, light and dark conditions).
3.2.1. Activated sludge simulating microcosm bioreactors
No stereoselectivity for ifosfamide (Fig. 6F), praziquantel (Fig. 6E),
tetramisole (Fig. 6D) and ketoprofen (Fig. 6B) was observed for the
activated sludge bioreactors, concentration levels and EF remained
unchanged over the 24 h under dark biotic and abiotic conditions. In a
study about the elimination of anticancer drugs during conventional
activated sludge wastewater using a fungal treatment it was observed
that ifosfamide and cyclophosphamide were quite inalterable, in con-
trast with the other anticancer drugs, and it was suggested that more
specific biodegradation systems (bacteria, another fungi, etc.) might be
needed (Ferrando-Climent et al., 2015). In the case of praziquantel
advanced oxidation technologies with UV-C/TiO2 with or without
scavengers (H2O2) are necessary to degrade it (Čizmić et al., 2017b;
Havliková et al., 2016). A slight decrease in tetramisole concentration
(19%; Fig. S7D) was observed under biotic conditions, but neither of its
enantiomers showed to be most preferably degraded. Concentration
levels of ketoprofen enantiomers remained constant through the whole
24 h experiment (Fig. S7B). Non-enantioselective transformations and
low removal have been previously reported for both ketoprofen en-
antiomers in a membrane bioreactor (Hashim et al., 2011), an activated
sludge bioreactor (Caballo et al., 2015; Escuder-Gilabert et al., 2018) or
in an enzymatic membrane bioreactor (Nguyen et al., 2017) pointing to
the presence of the carboxylic group as responsible for being resistant to
enzymatic degradation.
Stereoselective degradation was observed for naproxen (Fig. 6A),
indoprofen (Fig. 6C), chloramphenicol (Fig. 6H) and carbamazepine
metabolite (Fig. 6G).
The initial excess of S-(+)-naproxen would normally help to ob-
serve changes in the EF during microcosm experiments. After 3 h in the
biotic reactor the concentration of the enantiomers of naproxen
were< LOD. Although R/S(± )-naproxen was used to feed the ex-
periment, S-(+)-naproxen was degraded faster than its antipode (Fig.
S7A) or chiral inversion took place. In the abiotic experiment, the re-
moval of naproxen enantiomers was slower, it reached 50% after 24 h
(Fig. S7A). The most surprising observation to emerge during the ex-
periment was the increase in absolute concentration of R-(−)-naproxen
compared to the initial point which caused a change in the EF from 0.79
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to 0.54 (p < 0.01) after 24 h. Although unidirectional chiral inversion
of profens have mostly been reported (Hashim et al., 2011; Kasprzyk-
Hordern, 2010) our results could indicate bidirectional inversion of
naproxen enantiomers during microcosm experiments. This compound-
specific bidirectional inversion has been reported for naproxen (14% of
R-(−)-naproxen was inverted to the S-enantiomer whereas only 4% of
S-(+)-naproxen was inverted to R-(−)-naproxen) (Nguyen et al.,
2017)). The opposite behaviour of the EF under biotic and abiotic
conditions could be explained due to a combination of chiral inversion
and enantioselective degradation of S-(+)-naproxen in the biotic ex-
periment. Complete degradation of indoprofen was achieved after 5 h of
incubation (Fig. S7C) in the biotic activated sludge microcosm. The EF
value of indoprofen was also altered. It changed from an initial EF of
0.52 ± 0.01 to an EF of 0.38 ± 0.01 in 5 h (p < 0.05). To the best of
our knowledge, this is the first time degradation of chiral indoprofen
has been evaluated. It is well established that profens undergo chiral
inversion during metabolism (Khan et al., 2014; Sanganyado et al.,
2017), therefore changes in the EF values during biodegradation pro-
cesses have been mainly explained by faster degradation of one en-
antiomer over the other or chiral inversion (Rossetti et al., 1992).
Enantioselective degradation was observed for chloramphenicol
under biotic (EF 0.45 ± 0.01 to 0.37 ± 0.04) and most surprisingly
under abiotic (EF 0.52 ± 0.03 to 0.40 ± 0.01) conditions (Fig. 6H). It
led to the enrichment of the 1R,2R-(−)-enantiomer in the system which
is the only one of the possible eight different isomers of chlor-
amphenicol with reported antimicrobial activity (Shabad et al., 1977).
1R,2R-(−)-chloramphenicol was removed from the aqueous phase by
49% and 35% under biotic and abiotic conditions respectively in 24 h;
concentration of 1S,2S-(+)-chloramphenicol was attenuated by 65%
and 60% under biotic and abiotic conditions, respectively (Fig. S7H).
Enantioselective degradation is often observed by the result of micro-
bial activity (Hashim et al., 2011). The degree and direction of chiral
inversion in different organisms depend on multiple enzymes
(Kasprzyk-Hordern, 2010; Khan et al., 2014; Sanganyado et al., 2017),
but so far chiral inversion of chloramphenicol has not been reported.
Changes in the EF value in the abiotic activated sludge were unexpected
and they will need further research to explain them. It has been re-
ported that the bacteriostatic effects of sodium azide appear to be
limited to Gram-negative Bacteria, whereas Gram-positive Bacteria are
mostly resistant to sodium azide (Lichstein, 1944; Stannard and
Horecker, 1948). Therefore, the presence of sodium azide-resistant
bacteria could have preferentially degraded one enantiomer over the
other. Another explanation could be stereoselective sorption.
Sanganyado et al. (2017) pointed out that chiral minerals and organic
matter may serve as a chiral environment resulting in one enantiomer
being less available for transport, microbial degradation or uptake by
non-target organisms than the other.
Under biotic conditions, the absolute concentration of 10,11-di-
hydro,10-hydroxycarbamazepine enantiomers remained constant
throughout the 24 h experiment (Fig. 6G). However, after 8 h the EF
value (0.47 ± 0.02) started to increase until it reached 0.63 ± 0.07 in
24 h. In the abiotic reactor the concentration of both enantiomers
were< LOD after 8 h with no stereoselectivity observed.
3.2.2. River water simulating microcosms
The results of the mixed-compound river water microcosms
Fig. 5. Concentration (represented by bars) and enantiomeric fraction (represented by symbols) of R/S(± )-tetramisole, R/S(± )-10,11-dihydro-10-hydro-
xycarbamazepine, R/S(± )-naproxen, R/S(± )-fexofenadine and R/S(± )-cetirizine in upstream and downstream river water of Sites A–D.
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indicated that R/S(± )-ifosfamide was not degraded over the course of
the 30 days experiment in biotic and/or abiotic conditions both in the
presence and absence of light in river water bioreactors (Figs. 6F, S7F).
Ifosfamide has been shown to exhibit poor biodegradability and neg-
ligible light absorption in the solar wavelength range (Buerge et al.,
2006; Kümmerer et al., 1997), also the presence of halogenated func-
tional groups in its molecular structure may contribute to hinder
aerobic biodegradation (Tadkaew et al., 2011).
R/S(± )-Praziquantel (Figs. 6E, S7E) and R/S(± )-10,11-dihy-
droxy,10-hydroxycarbamazepine (Figs. 6G, S7G) were also considered
persistent but in contrast to ifosfamide concentration levels of both
enantiomers of praziquantel and carbamazepine metabolite decreased
under biotic light conditions although not stereoselectively. Few reports
have shown that praziquantel is photodegraded when directly exposed
to sunlight in aqueous media but over a period of few months (Suleiman
et al., 2004). A combination of microbial and photochemical degrada-
tion could speed up the degradation of praziquantel and account for the
changes observed in the biotic light experiment over a period of
30 days. Regarding carbamazepine metabolites they have been reported
to be as persistent as the parent compound during wastewater treat-
ment (Leclercq et al., 2009). Enantioselective degradation was observed
in the biotic activated sludge microcosm but not in the river water
microcosm what would indicate high biomass density or specialized
microbial communities are needed to enantioselectively degrade this
compound.
The combination of photochemical and biological degradation was
key to dissipate the concentration of R/S(± )-ketoprofen (Figs. 6B,
S7B) and R/S(± )-naproxen (Figs. 6A, S7A). Photodegradation had an
important impact on concentration whereas biodegradation had it also
on stereoselectivity. By day 5 ketoprofen enantiomers were removed by
98% of their initial concentration in biotic and abiotic light conditions.
Photodegradation of naproxen was slower, by day 30, S-(+)-naproxen
was removed by 84% and 79% and R-(−)-naproxen by 79% and 68% in
the biotic and abiotic light microcosms, respectively. When light was
not present stereoselective biodegradation was clearly observed. The R-
enantiomers of naproxen and ketoprofen were preferentially degraded
over the S-enantiomers. At the beginning of the experiment the EF of
ketoprofen was 0.50 ± 0.01 and the EF of naproxen was 0.66 ± 0.02
(due to the presence of endogenous S-(+)-naproxen), half way the EF of
both cPACs increased (EF=0.71 ± 0.01 ketoprofen, p < 0.001, day
12; EF=0.73 ± 0.04 naproxen, p < 0.05, day 22) and they reached
EF= 1 (p < 0.001) at the end of the experiment.
Among the studied profens, R/S(± )-indoprofen (Figs. 6C, S7C)
turned to be more stable to photochemical and biological degradation.
The dissipation of indoprofen enantiomers happened only under biotic
light conditions and at the end of the experiment (30 days) suggesting
more time is needed to achieve complete removal. An excess of in-
doprofen E1 was found at the beginning of the experiment
(EF=0.59 ± 0.01), but at the end of the experiment the concentration
of E1 and E2 were similar probably as a result of E1 being degraded
faster than E2 or due to chiral inversion (EF=0.51 ± 0.01). In vitro
metabolic inversion of R/S(± )-indoprofen towards an excess of the S-
enantiomer was previously reported after liver microsomes where in-
cubated with the racemic mixture and the individual enantiomers
(Rossetti et al., 1992).
Photodegradation was an important process to dissipate the con-
centration of R/S(± )-chloramphenicol (Figs. 6H, S7H) and R/S
(± )-tetramisole (Figs. 6D, S7D) in the microcosm experiments. R/S
(± )-chloramphenicol was not present after 12 and 15 days in the
biotic light and abiotic light reactors, respectively. Biotic processes also
contributed to the degradation of R/S(± )-chloramphenicol although
in a minor extent than photolysis. When biotic processes were involved
1R,2R-(−)-chloramphenicol was degraded faster than the 1S,2S-
(+)-enantiomer (EF= 0.77 ± 0.20). This behaviour was opposite to
the one observed in the activated sludge microcosm in which the EF
value decreased. Different microbial communities and the presence of
microalgae could explain these differences. As an example, different
environmental studies have reported varied results showing S-
(−)-metoprolol enrichment (Evans et al., 2017) and R-(+)-metoprolol
enrichment (Ribeiro et al., 2013) in activated sludge microcosms or the
preferential degradation of S-(−)-metoprolol by microalgae (Lv et al.,
2018). Changes in the biotic light reactor could not be observed because
photolysis was such an important dissipation effect that probably
overshadowed the preferential degradation of one over the other.
Photodegradation has been reported as an important process for the
degradation of chloramphenicol in natural waters (Trovo et al., 2014).
Regarding R/S(± )-tetramisole, 73% and 40% of both enantiomers
were removed under biotic and abiotic light conditions, respectively,
whereas under dark conditions removal efficiency was under 10% after
30 days. As it happened, neither of the tetramisole enantiomers was
shown to be more preferentially degraded than the other in the acti-
vated sludge microcosms.
4. Conclusions
In this study, we performed a catchment-scale study (macrocosm) to
investigate the occurrence, removal efficiencies and enantiomeric dis-
tribution of a comprehensive set of cPACs in 5 major STWs and in re-
ceiving waters of the largest river catchment in Southwest England. At the
same time we performed controlled lab-scale microcosm studies in simu-
lated activated sludge bioreactors and river water microcosm to evaluate
stereoselective degradation of cPACs and to investigate the role of EF as a
marker of in situ biodegradation. cPAC concentrations in influent waste-
water were: (i) found to vary significantly spatially and temporally and (ii)
are enriched in one of the enantiomers as a signature of human and mi-
crobial metabolism despite being marketed as racemic mixtures. Receiving
waters revealed a chiral signature that corresponded to the one observed
in effluent wastewaters. Stereoselective degradation during wastewater
treatment was observed in the case of naproxen, ketoprofen, cetirizine,
ifosfamide and 10,11-dihydroxy-10-hydroxycarbamazepine. It is hy-
pothesized that differences in density and diversity of microbial popula-
tion resulted in wastewater treatment dependent stereoselectivity and also
in the extent of enantiomer-specific fate. Higher stereoselectivity was ob-
served for naproxen in TF and for cetirizine in TF and AS.
Both activated and river water simulated microcosm confirmed that
enantioselective degradation was biological in nature. It led to an excess of
S-(+)-naproxen, 1R,2R-(−)-chloramphenicol and one of the enantiomers
of indoprofen and 10,11-dihydroxy-10-hydroxycarbamazepine in acti-
vated sludge microcosm and to an excess of S-(+)-naproxen, S-(+)-ke-
toprofen, 1S,2S-(+)-chloramphenicol and one of the enantiomers of in-
doprofen. Differences in the preferential degradation of one enantiomer in
both microcosms could be attributed to biomass density, nature of mi-
crobial community and time of exposition. Further work is required to
study this phenomenon.
Results from our large scale river catchment monitoring study and
lab simulated microcosms show the impact of stereoisomerism of cPACs
on their fate. It is hypothesized that cPACs stereoselective fate will have
effects on biota. As two enantiomers of the same compound show dif-
ferent biological effects (e.g. toxicity), their non-racemic presence in
the environment might lead to inaccurate environmental risk assess-
ment (ERA). This is because current ERA approaches do not require
analysis at enantiomeric level.
Fig. 6. Concentration (represented by bars) and enantiomeric fraction (represented by symbols) of naproxen (A), ketoprofen (B), indoprofen (C), tetramisole (D),
praziquantel (E), ifosfamide (F), 10,11-dihydro-10-hydroxycarbamazepine (G) and chloramphenicol (H) enantiomers in mixed compound bioreactors in activate
sludge and river water.
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Supplementary material 
Table S1. Site information of studied STWs and corresponding river locations   
Site 
Sewer 
residence 
timea (h) 
STW 
secondary 
process 
SRT 
(d) 
HRTa 
(h) 
Population 
served 
Mean flow 
(m3 d-1) 
Effluent 
dilution 
factor 
River sampling, distance 
to discharge point (km) 
Upstream Downstream 
A <0.5-4 AS 19 46.2 37,000 8,242±3,085 14 0.5 n/a 
B <0.5-4 TF n/a 24.5 67,870 11,202±3,202 15 0.5 0.5 
C <0.5-9 TF n/a 13.9 105,847 24,875±2,167 15 2 2 
D <0.5-2 TF n/a 17.6 17,638 2,924±199 113 1 1 
E <1-24 
90% SBR 
10% AS 
4 
8 
10.9 
25.8 
909,617 153,061±12,245 n/ab - - 
Key: STW, wastewater treatment process; SRT, solids retention time; HRT, hydraulic retention time; AS, 
activated sludge; TF, trickling filter; SBR, sequencing batch reactor 
aUnder summer (dry weather) flow 
bEffluent discharged into estuary 
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Figure S1. Catchment area schematic illustrating sampling points   
 
 
Figure S2. Schematic for the river water (A) and activated sludge (B) microcosm bioreactors.   
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Figure S3. pH, dissolved oxygen (DO) and temperature (T) recorded during 24 h in the activated sludge 
microcosm bioreactors and during 30 days in the river water microcosm bioreactors.   
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Figure S4. Concentration (μg L-1) of cPACs in influent and effluent wastewater of STW A-E and upstream and 
downstream river water of each site (STW A-D). Lines in each box show the lower (5%), median (50%) and 
upper (95%) percentile. Lines from each box show maximum and minimum concentration values. The point 
inside each box shows the average concentration. *Data not available for R/S(±)-ibuprofen in influent 
wastewater. 
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Figure S5. Concentration (μg L-1) of cPACs in influent (A) and effluent (B) wastewater and upstream (C) and 
downstream (D) river water during a week. *Data not available for R/S(±)-ibuprofen in influent wastewater. 
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Figure S6. Enantiomeric fraction (EF) (mean ± SD) of cPACs in influent and effluent wastewater of activated 
sludge (AS), trickling filter beds (TF) and sequencing batch reactors (SBR). Significance was assessed by 
multiple ANOVA using Sidak’s multiple comparisons test, *p<0.05; **p<0.01, ****p<0.0001. # Data not 
available for R/S(±)-ibuprofen in influent wastewater. 
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Figure S7. Removal of naproxen (A), ketoprofen (B), indoprofen (C), tetramisole (D), praziquantel (E), 
ifosfamide (F), 10,11-dihydro-10-hydroxycarbamazepin (G) and chloramphenicol (H) enantiomers in mixed 
compound bioreactors in activate sludge and river water. 
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Figure S7. (Continuation). 
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